Clazakizumab for kidney failure patients on dialysis
Part of Heart & circulation, Hormones & metabolism, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests an experimental drug called clazakizumab (CSL300) to see if it can reduce inflammation and lower the risk of heart problems in people with kidney failure who are on dialysis. It may help if you have diabetes or heart disease and have high inflammation levels.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been on dialysis for at least 12 weeks.
- Your blood test shows a high level of inflammation (hs-CRP at least 2.0 mg/L).
- You have diabetes or a history of heart disease/stroke (ASCVD).
- You are not currently taking drugs that suppress your immune system.
- You do not have a serious active infection or a history of certain infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether clazakizumab can reduce the risk of heart attacks or strokes in people with high levels of inflammation (measured by a blood test called hsCRP) and conditions like heart disease, obesity, diabetes, high blood pressure, or kidney disease. If you qualify, you'll receive either the study drug or a placebo to see if it helps lower your risk.
This trial tests a new study drug called AZD1613 for adults with a certain type of kidney disease (ADPKD). Researchers want to see if it is safe, how the body handles it, and what the right dose might be.
This study tests an investigational drug called ALN-ANG3 to see if it can help people with diabetic kidney disease. The drug may reduce kidney damage and slow down the loss of kidney function. If you join, you will get the study drug or a placebo (a dummy shot) and be followed by a study doctor.
This study tests three experimental drugs (frexalimab, brivekimig, and rilzabrutinib) for people ages 16 to 75 with a type of kidney disease called primary FSGS or minimal change disease. The goal is to see if these drugs can reduce protein in your urine and help protect your kidneys.
This study tests how a new drug called CSL300 (clazakizumab) works in the body of people with end-stage kidney disease who are on dialysis. Researchers want to understand if it's safe and how your body processes it.
This trial tests three experimental antibodies given to people with end-stage kidney disease who are on hemodialysis. It aims to see if these drugs are safe and how they affect blood clotting in this group.
Hear when a new End Stage Kidney Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.